- During the September quarter, Starpharma (SPL) achieved several milestones with its SPL7013 COVID-19 nasal spray
- Additionally, the pharmaceutical company made progress with its Dendrimer Enhanced Product (DEP) candidates and VivaGel BV
- The DEP candidates used to treat varying tumours and all are progressing well with phase 2 trials
- The product launched in the Nordic region and regulatory approvals were received for countries in Africa and the Middle East
- As of September 30, Starpharma had a cash balance of $24.9M, a decrease from the $36.8M in the prior corresponding period
- Net operating cash outflows were $4.7 million, with the majority going towards research and development, and staff costs
